Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease

Errol B. De Souza, Peter J. Whitehouse, Susan E. Folstein, Donald L. Price, Wylie W. Vale

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Corticotropin-releasing hormone-like immunoreactivity (CRH-IR) was measured in control and Huntington's disease brain tissues obtained postmortem. The concentration of CRH-IR was markedly decreased in the caudate/putamen in Huntington's disease; the concentration of somatostatin-like immunoreactivity measured in the same extracts was significantly increased in the caudate/putamen in Huntington's disease compared with the control group. In contrast to previously reported decreases in CRH-IR in the cerebral cortex in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, no significant differences were observed in the concentrations of CRH-IR between controls and Huntington's disease in frontal, parietal, temporal, occipital and cingulate cortex and in globus pallidus.

Original languageEnglish (US)
Pages (from-to)355-359
Number of pages5
JournalBrain research
Issue number2
StatePublished - Dec 29 1987


  • Basal ganglia
  • Corticotropin-releasing hormone
  • Huntington's disease
  • Postmortem human brain
  • Radioimmunoassay
  • Somatostatin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease'. Together they form a unique fingerprint.

Cite this